Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is a financially strong company with a unique and comprehensive approach in the fertility benefits space, leading to strong growth and profitability. They prioritize customer satisfaction and early renewal, and have a diverse range of clients, giving them confidence in their long-term growth. While there are potential risks and delays in new revenue generation, Progyny's positive earnings for 1Q and ongoing efforts to reach a wider audience through marketing newer services bode well for their future prospects.

Bears say

Progyny is facing significant challenges as it operates in a highly competitive market for fertility benefits solutions. While the company has a strong attachment rate and is able to reduce costs and improve outcomes through integration with the clinical workflow, there are concerns around alternative medication channels and fragmentation of benefits. Additionally, with only 2.5% of US births resulting from assisted reproductive technology, adoption of fertility coverage still has a long runway. Furthermore, the company's reliance on utilization for annual performance makes it vulnerable to fluctuations in human behavior.

Progyny (PGNY) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 10 analysts, Progyny (PGNY) has a Buy consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.